Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1376-1384

  Ghadersohi, Ali ^a   Odunsi, Kunle ^a   Zhang, Shaozeng ^a   Azrak, Rami G ^a   Bundy, Brian N ^a   Manjili, Masoud H ^b   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Ovarian cancer; PDEF; Selenium; Survivin; Vitamin D3

Indexed keywords

SELENIUM; SURVIVIN; TRANSCRIPTION FACTOR ETS; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; EARLY CANCER; FEMALE; HUMAN; HUMAN CELL; LOG RANK TEST; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ETS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 49749143436     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23667     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305-314.
3. Ghadersohi A, Chitta K, Greco WR, Harvey S, Winston J, Slocum H, Odunsi K, Sood AK. Tumour antigens and markers for breast and ovarian cancers. Front Biosci 2002;7:48-57.
4. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, et al. Genetic analysis of early-versus late-stage ovarian tumour. Cancer Res 2001;61:5895-904.
5. Nozawa M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, Nishimune Y, Nozaki M. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 2000;60:1348-52.
6. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003;63:4626-31.
7. Ghadersohi A, Sood AK. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumours and is a candidate breast tumour marker and a breast tumour antigen. Clin Cancer Res 2001;7:2731-8.
8. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 2005;65:11572-80.
9. Tsujimoto Y, Nonomura N, Takayama H, Yomogida K, Nozawa M, Nishimura K, Okuyama A, Nozaki M, Aozasa K. Utility of immunohistochemical detection of prostate-specific Ets for the diagnosis of benign and malignant prostatic epithelial lesions. Int J Urol 2002; 9:167-72.
10. Ghadersohi A, Dalin P, Fayazi Z, Hicks DG, Winston JS, Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibit breast cancer cell growth in vitro and xenograft tumour formation in vivo. Breast Cancer Res Treat 2007; 102:19-30.
11. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007;67:1618-25.
12. Gu X, Zerbini LF, Out HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cell. Cancer Res 2007;67:4219-26.
13. Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK. Prostate-derived Ets Factor is overexpressed in serous epithelial ovarian tumours. Int J Gynecol Pathol 2007;26:10-15.
14. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T, Li F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence selective DNA-binding antitumour agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity. J Biol Chem 2005;280:9745-51.
15. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-9.
16. Zhao H, Whitfield LM, Xu T, Botstein D, Brooks JD. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 2004;15:506-19.
17. Clement IP. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-4.
18. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours. International classification of tumours. World Health Organization, 1973.
19. Kaplan EL, Meir P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-86.
20. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, Mcpherson K, Peto J, Smith PG. Design and analysis of randomized clinical trails requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
21. Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther 2006;5:2540-8.
22. 3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 2005;24:1385-95.
23. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Aciemo JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006.
24. Zhang X, Jiang F, Li P, Li C, Qiuping Ma, Nicosia SV, Bai W. Growth suppression of ovarian cancer xenografts in nude mice By Vitamin D analogue EB1089. Clinical Cancer Res 2005;11:323-8.
25. Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev 2002;21:147-58.
26. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005;41:2462-78.
27. Li F. Role of survivin and its splice variants in tumourigenesis. Br J Cancer 2005;92:212-6.
28. Li F. Survivin Study: what is the next wave? J Cell Physiol 2003; 197:8-29.
29. Vijayakumar S, Mehta RR, Boemer PS, Packianathan S, Mehta RG. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 2005;11:362-73.
30. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;2:305-11.